SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Rubius Therapeutics, Inc. – ‘10-K’ for 12/31/20 – ‘R10’

On:  Tuesday, 2/23/21, at 8:43am ET   ·   For:  12/31/20   ·   Accession #:  1558370-21-1412   ·   File #:  1-38586

Previous ‘10-K’:  ‘10-K’ on 3/12/20 for 12/31/19   ·   Next:  ‘10-K’ on 2/25/22 for 12/31/21   ·   Latest:  ‘10-K’ on 2/27/23 for 12/31/22   ·   14 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/23/21  Rubius Therapeutics, Inc.         10-K       12/31/20   82:12M                                    Toppan Merrill Bridge/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.86M 
 2: EX-21.1     Subsidiaries List                                   HTML     23K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     23K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
14: R1          Document and Entity Information                     HTML     88K 
15: R2          Consolidated Balance Sheets                         HTML    101K 
16: R3          Consolidated Balance Sheets (Parenthetical)         HTML     40K 
17: R4          Consolidated Statements of Operations and           HTML     70K 
                Comprehensive Loss                                               
18: R5          Consolidated Statements of Operations and           HTML     26K 
                Comprehensive Loss (Parenthetical)                               
19: R6          Consolidated Statements of Convertible Preferred    HTML    105K 
                Stock and Stockholders' Equity (Deficit)                         
20: R7          Consolidated Statements of Convertible Preferred    HTML     25K 
                Stock and Stockholders' Equity (Deficit)                         
                (Parenthetical)                                                  
21: R8          Consolidated Statements of Cash Flows               HTML    131K 
22: R9          Nature of the Business and Basis of Presentation    HTML     32K 
23: R10         Summary of Significant Accounting Policies          HTML    119K 
24: R11         Investments and Fair Value of Financial Assets and  HTML    120K 
                Liabilities                                                      
25: R12         Property, Plant and Equipment, Net                  HTML     64K 
26: R13         Debt                                                HTML     52K 
27: R14         Convertible Preferred Stock                         HTML     27K 
28: R15         Warrants to Purchase Convertible Preferred Stock    HTML     26K 
29: R16         Equity                                              HTML     29K 
30: R17         Stock-Based Compensation                            HTML    139K 
31: R18         Income Taxes                                        HTML     94K 
32: R19         Commitments and Contingencies                       HTML     30K 
33: R20         Leases                                              HTML     81K 
34: R21         Net Loss Per Share                                  HTML     56K 
35: R22         Related Parties                                     HTML     29K 
36: R23         Selected Quarterly Financial Data (Unaudited)       HTML     79K 
37: R24         Summary of Significant Accounting Policies          HTML    170K 
                (Policies)                                                       
38: R25         Summary of Significant Accounting Policies          HTML     87K 
                (Tables)                                                         
39: R26         Investments and Fair Value of Financial Assets and  HTML    121K 
                Liabilities (Tables)                                             
40: R27         Property, Plant and Equipment, Net (Tables)         HTML     47K 
41: R28         Accrued Expenses and Other Current Liabilities      HTML     38K 
                (Tables)                                                         
42: R29         Debt (Tables)                                       HTML     49K 
43: R30         Stock-Based Compensation (Tables)                   HTML    130K 
44: R31         Income Taxes (Tables)                               HTML     91K 
45: R32         Leases (Tables)                                     HTML     76K 
46: R33         Net Loss Per Share (Tables)                         HTML     57K 
47: R34         Selected Quarterly Financial Data (Unaudited)       HTML     79K 
                (Tables)                                                         
48: R35         Nature of the Business and Basis of Presentation    HTML     58K 
                (Details)                                                        
49: R36         Summary of Significant Accounting Policies          HTML     39K 
                (Details)                                                        
50: R37         Summary of Significant Accounting Policies -        HTML     37K 
                Estimated useful life (Details)                                  
51: R38         Summary of Significant Accounting Policies -        HTML    113K 
                Recently Adopted Accounting Pronouncements                       
                (Details)                                                        
52: R39         Investments and Fair Value of Financial Assets and  HTML     73K 
                Liabilities (Details)                                            
53: R40         Property, Plant and Equipment, Net (Details)        HTML     65K 
54: R41         Accrued Expenses and Other Current Liabilities      HTML     36K 
                (Details)                                                        
55: R42         Debt (Details)                                      HTML     82K 
56: R43         Debt - Current and Non current (Details)            HTML     35K 
57: R44         Convertible Preferred Stock (Details)               HTML     56K 
58: R45         Warrants to Purchase Convertible Preferred Stock    HTML     45K 
                (Details)                                                        
59: R46         Equity (Details)                                    HTML     62K 
60: R47         Stock-Based Compensation (Details)                  HTML     55K 
61: R48         Stock-Based Compensation - Employees, directors     HTML     31K 
                and non-employees (Details)                                      
62: R49         Stock-Based Compensation - Option activity          HTML     85K 
                (Details)                                                        
63: R50         Stock-Based Compensation - Performance based stock  HTML     84K 
                options (Details)                                                
64: R51         Stock-Based Compensation - Restricted Common Stock  HTML     87K 
                (Details)                                                        
65: R52         Stock-Based Compensation - Compensation expense     HTML     64K 
                (Details)                                                        
66: R53         Income Taxes (Details)                              HTML     48K 
67: R54         Income Taxes - U S federal statutory income tax     HTML     42K 
                rate (Details)                                                   
68: R55         Income Taxes - Net deferred tax assets (Details)    HTML     53K 
69: R56         Income Taxes - Valuation allowance for deferred     HTML     27K 
                tax assets (Details)                                             
70: R57         Commitments and Contingencies - Collaborative       HTML     31K 
                Arrangements and Non-collaborative Arrangement                   
                (Details)                                                        
71: R58         Commitments and Contingencies - Defined             HTML     31K 
                Contribution Plan (Details)                                      
72: R59         Leases (Details)                                    HTML     57K 
73: R60         Leases - Minimum lease payments (Details)           HTML     42K 
74: R61         Leases - Lease Portfolio (Details)                  HTML     47K 
75: R62         Net Loss Per Share - Weighted Average Shares        HTML     39K 
                (Details)                                                        
76: R63         Net Loss Per Share - Antidilutive Securities        HTML     35K 
                (Details)                                                        
77: R64         Related Parties (Details)                           HTML     66K 
78: R65         Selected Quarterly Financial Data (Unaudited)       HTML     41K 
                (Details)                                                        
80: XML         IDEA XML File -- Filing Summary                      XML    150K 
13: XML         XBRL Instance -- ruby-20201231x10k_htm               XML   2.26M 
79: EXCEL       IDEA Workbook of Financial Reports                  XLSX    114K 
 9: EX-101.CAL  XBRL Calculations -- ruby-20201231_cal               XML    175K 
10: EX-101.DEF  XBRL Definitions -- ruby-20201231_def                XML    641K 
11: EX-101.LAB  XBRL Labels -- ruby-20201231_lab                     XML   1.50M 
12: EX-101.PRE  XBRL Presentations -- ruby-20201231_pre              XML   1.12M 
 8: EX-101.SCH  XBRL Schema -- ruby-20201231                         XSD    179K 
81: JSON        XBRL Instance as JSON Data -- MetaLinks              398±   605K 
82: ZIP         XBRL Zipped Folder -- 0001558370-21-001412-xbrl      Zip    937K 


‘R10’   —   Summary of Significant Accounting Policies


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.20.4
Summary of Significant Accounting Policies
12 Months Ended
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the preferred stock warrant liability prior to the IPO and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.

The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.

Concentrations of Credit Risk and of Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and investments. The Company’s cash, cash equivalents and investments as of December 31, 2020 consisted of money market accounts, U.S. government money market funds, U.S government treasury bills and U.S. government treasury notes. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.

Deferred Offering Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.

Deferred Financing Costs

The Company capitalizes certain legal and other third-party fees that are directly associated with obtaining access to capital under credit facilities. Deferred financing costs incurred in connection with obtaining access to capital are recorded in other assets and are amortized over the term of the credit facility. Deferred financing costs related to a recognized debt liability are recorded as a reduction of the carrying amount of the debt liability and amortized to interest expense using the effective interest method over the repayment term.

Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.

Restricted Cash

As of both December 31, 2020 and 2019, the Company maintained letters of credit totaling $1.7 million for the benefit of the landlords of its leased properties. The Company was required to maintain separate cash balances of these amounts to secure the letters of credit. Related to these separate cash balances, the Company included $0.1 million in prepaid expenses and other current assets and $1.6 million in restricted cash (non-current) in its consolidated balance sheet as of December 31, 2020. The Company classified $1.7 million as restricted cash (non-current) and it did not have any restricted cash (current) in its consolidated balance sheet as of December 31, 2019.

Cash, cash equivalents and restricted cash presented in the accompanying consolidated statement of cash flows was $92.9 million, $93.6 million and $309.4 million for the years ended December 31, 2020, 2019 and 2018, respectively, of which $1.7 million, $1.7 million and $2.3 million was restricted cash, respectively.

Property, Plant and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:

    

Estimated useful life

Computer equipment

 

3 years

Laboratory equipment

 

5 years

Furniture and fixtures

 

7 years

Manufacturing equipment

10 years

Manufacturing facility

 

30 years

Leasehold improvements

 

Shorter of life of lease or 10 years

Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred.

Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a

long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the periods presented.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company’s cash equivalents and investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company’s long-term debt approximates its fair value due to its variable interest rate, which approximates a market interest rate.

Investments

The Company’s investments are classified as available-for-sale and are carried at fair value. Realized gains and losses and declines in value are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such investments are available for current operations.

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses, which changes the impairment model for most financial assets, including the Company’s investments. The Company adopted the standard effective January 1, 2020 using a prospective transition method.

The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. No such credit losses were recorded during the periods presented.

Leases

At the inception of an arrangement as lessee or lessor, the Company determines whether the arrangement is or contains a lease. Operating lease cost is recognized over the lease term on a straight-line basis. Variable lease cost and short-term leases (lease terms less than 12 months) are recognized as incurred. For both lessee and lessor arrangements, variable lease payments are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are expensed when incurred. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option.

For lessee arrangements, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.

The Company has elected the following lease policies at the inception of a lease: (1) for lessee and lessor arrangements within all asset classes, combine lease and non-lease components as a single component, with the lease expense recognized over the expected term on a straight-line basis and (2) for lessee arrangements, apply short-term lease exemption for all leases that qualify, where a right-of-use asset or lease liability will not be recognized for leases with terms of one year or less.

Segment Information

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is developing product candidates based on genetically engineered red blood cells for the treatment of patients with severe diseases. All of the Company’s tangible assets are held in the United States.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials, as well as the cost of licensing technology.

Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.

Research and Manufacturing Contract Costs and Accruals

The Company has entered into various research and development and manufacturing contracts with research institutions and other companies both inside and outside of the U.S. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end with those third parties to record accruals for estimated ongoing research and development costs. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.

Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

Stock-Based Compensation

The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company’s common stock. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company measures restricted stock units with service-based vesting as the market value of the Company’s stock on the date of grant. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures as they occur and records compensation cost assuming all option holders will complete the requisite service period. If an award is forfeited, the Company reverses compensation expense previously recognized in the period the award is forfeited.

For stock-based awards with market-based vesting conditions, the Company measures the fair value on the date of grant using a Monte Carlo simulation model. When service-based vesting conditions also exist, the Company recognizes stock-based compensation expense using the graded-vesting method over the longer of the derived service period from the market condition or the required service period. In accordance with accounting guidance for awards with market conditions, the stock-based compensation expense will be recognized over the appropriate period regardless of whether the award achieves the market condition and will only be adjusted to the extent the service condition is not met. When an award contains a market-based vesting condition and a performance-based vesting condition where both must be achieved to earn the award, the Company recognizes stock-based compensation expense over the longer of the derived service period from the market condition or the period estimated for the performance-based vesting condition to be achieved. The Company begins recording stock-based compensation expense for this type of award once the achievement of the performance-based vesting condition becomes probable regardless of whether the market condition has been achieved.

For restricted stock awards under which restricted common stock is purchased by the holder with a promissory note treated as a nonrecourse note for accounting purposes, the Company measures the fair value of the award using the Black-Scholes option-pricing model.

The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.

Comprehensive Loss

Comprehensive loss includes net loss, as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2020, 2019 and 2018, the Company’s only element of other comprehensive loss was unrealized gains (losses) on investments.

Net Income (Loss) per Share

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding common stock equivalents. Accordingly, in

periods in which the Company reported a net loss, dilutive common shares were not assumed to have been issued as their effect was anti-dilutive, and as a result, diluted net loss per common share was the same as basic net loss per common share.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties.

Recently Adopted Accounting Pronouncements

ASU No. 2018-07, Compensation Stock Compensation

In June 2018, the Financial Accounting Standards Board, (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, Compensation — Stock Compensation (Topic 718), Improvements to Non-Employee Share-Based Payment Accounting (“ASU 2018-07”). This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation.

Effective January 1, 2018, the Company early adopted ASU 2018-07 by remeasuring outstanding equity-classified awards issued to non-employees for which a measurement date had not been established as of January 1, 2018 through a cumulative-effect adjustment to accumulated deficit as of January 1, 2018. The Company elected to estimate the expected term of options utilizing the “simplified” method for both employee and non-employee options that qualify as “plain-vanilla” options. The Company elected to account for forfeitures for non-employee options as they occur rather than apply an estimated forfeiture rate to stock-based compensation expense.

The following table summarizes the cumulative effect to the Company’s consolidated balance sheet upon the adoption of ASU 2018-07 on January 1, 2018 (in thousands):

    

Balance at

    

    

Balance at

December 31, 2017

Adjustments

January 1, 2018

Additional paid-in capital

$

17,277

$

(92)

$

17,185

Accumulated deficit

(60,979)

92

(60,887)

The $0.1 million adjustment was the result of the change in fair value of the unvested awards, representing awards for which a measurement date had not been established, using an expected term rather than the contractual term of the awards.

As of the adoption date of January 1, 2018, the Company had 330,917 outstanding options to non-employees for which a measurement date had not been established. As of the adoption date of January 1, 2018, the Company had 4,767,014 shares of restricted common stock held by non-employees that were being accounted for as stock options for which a measurement date had not been established (see Note 10). The weighted average fair value of these awards was $5.88 per share as of January 1, 2018. The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of outstanding awards granted to non-employees for which a measurement date had not been established as of the adoption date of January 1, 2018:

Risk-free interest rate

2.3

%

Expected volatility

 

74

%

Expected dividend yield

 

Expected term (in years)

 

6.1

Common stock value

$

6.28

ASU No. 2016-02, Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized over the lease term based on an effective interest method for financing leases or on a straight-line basis for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less may be accounted for similar to previous guidance for operating leases under ASC 840. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2018 and for interim periods within those fiscal years.

ASU 2016-02 initially required adoption using a modified retrospective approach, under which all years presented in the financial statements would be prepared under the revised guidance. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which added an optional transition method under which financial statements may be prepared under the revised guidance for the year of adoption, but not for prior years. Under the latter method, entities will recognize a cumulative catch-up adjustment to the opening balance of retained earnings in the period of adoption.

The Company adopted ASC 842 using the modified retrospective approach with an effective date of January 1, 2019 for leases that existed on that date. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. This standard provides a number of optional practical expedients in transition. The Company applied the package of practical expedients to leases that commenced prior to the effective date, whereby it elected not to reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. The Company elected the short-term lease recognition exemption for all leases that qualify, where a right-of-use asset or lease liability will not be recognized for short term leases that have terms of one year or less. The most significant effects of adoption were the recognition of material new right-of-use assets and corresponding liabilities on its consolidated balance sheet related to its existing facility operating leases (see Note 13). In addition, the Company has a material lease where the Company was deemed the owner during the construction period and for which the construction was not complete as of January 1, 2019. The Company took control of the leased space during the first quarter of 2019, at which time the lease commenced. Under ASC 842, as the commencement date of this material lease had not occurred, the new right-of-use assets and corresponding liabilities related to this lease were not recognized on the consolidated balance sheet as of date of adoption, January 1, 2019, however, were recognized upon the commencement date of January 28, 2019. The adoption of this standard has had a material impact on the Company’s financial position but did not significantly affect the Company’s results of operations.

The following table summarizes the financial impact on the Company’s consolidated balance sheet upon the adoption of ASU 2016-02 and the cumulative effect adjustment on January 1, 2019 (in thousands):

    

Balance at

    

    

Balance at

December 31, 2018

Adjustments

January 1, 2019

Operating lease, right-of-use-asset

$

$

1,751

$

1,751

Property, plant and equipment, net

62,796

(45,142)

17,654

Deferred rent

143

(143)

Accrued expenses and other current liabilities

12,118

(4,451)

7,667

Lease financing obligation

41,441

(41,441)

Operating lease liabilities

616

616

Operating lease liabilities, net of current portion

1,226

1,226

Accumulated deficit

(150,082)

800

(149,282)

ASU No. 2018-15, Intangibles–Goodwill and Other–Internal-Use Software

In August 2018, the FASB issued ASU No. 2018-15, Intangibles–Goodwill and Other–Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard on January 1, 2019 on a prospective basis. The adoption did not have a material impact on the Company’s consolidated financial statements.

ASU No. 2016-13, Financial Instruments—Credit Losses

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard as of January 1, 2020 on a prospective basis. The adoption did not have a material impact on the Company’s consolidated financial statements.

ASU No. 2018-13, Fair Value Measurement

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB’s disclosure framework project. For all entities, this guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard as of January 1, 2020 on a prospective basis. The adoption did not have an impact on the Company’s consolidated financial statements.

ASU No. 2020-04, Reference Rate Reform

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides temporary optional expedients and exceptions to the US GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens of the expected market transition from LIBOR and other interbank offered rates to alternative reference rates.

For all entities, this guidance is effective as of issuance, March 12, 2020, through December 31, 2022. The Company adopted this standard as of March 12, 2020 on a prospective basis and is currently evaluating its contracts referencing LIBOR for reference rate replacement.

Recently Issued Accounting Pronouncements

ASU No. 2019-12, Simplifying the Accounting for Income Taxes

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (ASC 740). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
12/31/22
Filed on:2/23/218-K
For Period end:12/31/20
3/12/2010-K,  8-K,  S-8
1/1/20
12/31/1910-K,  4
12/15/19
1/28/19
1/1/19
12/31/1810-K,  10-K/A,  5
12/15/18
1/1/18
12/31/17
 List all Filings 


3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/18/21  Rubius Therapeutics, Inc.         8-K:1,9     3/16/21   12:582K                                   Toppan Merrill/FA
 3/18/21  Rubius Therapeutics, Inc.         424B5                  1:772K                                   Toppan Merrill/FA
 3/15/21  Rubius Therapeutics, Inc.         424B5                  1:774K                                   Toppan Merrill/FA


11 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/28/20  Rubius Therapeutics, Inc.         8-K:5,9     9/23/20   12:359K                                   Toppan Merrill/FA
 8/10/20  Rubius Therapeutics, Inc.         10-Q        6/30/20   53:5.3M                                   Toppan Merrill Bridge/FA
 5/11/20  Rubius Therapeutics, Inc.         10-Q        3/31/20   53:5M                                     Toppan Merrill Bridge/FA
 3/12/20  Rubius Therapeutics, Inc.         10-K       12/31/19   86:13M                                    Toppan Merrill Bridge/FA
11/14/19  Rubius Therapeutics, Inc.         10-Q        9/30/19   67:7.4M                                   Toppan Merrill Bridge/FA
 8/01/19  Rubius Therapeutics, Inc.         S-3                    7:1.7M                                   Toppan Merrill-FA
 5/15/19  Rubius Therapeutics, Inc.         10-K/A     12/31/18    5:313K                                   Toppan Merrill Bridge/FA
 7/23/18  Rubius Therapeutics, Inc.         8-K:5,8,9   7/17/18    3:223K                                   Toppan Merrill/FA
 7/09/18  Rubius Therapeutics, Inc.         S-1/A                 10:5.6M                                   Toppan Merrill-FA
 7/02/18  Rubius Therapeutics, Inc.         S-1/A                  7:1M                                     Toppan Merrill-FA
 6/22/18  Rubius Therapeutics, Inc.         S-1                   18:11M                                    Toppan Merrill-FA
Top
Filing Submission 0001558370-21-001412   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 10:33:26.1am ET